Inhaled interferon could be new weapon against severe RSV in young children
NCT ID NCT06363370
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This phase 3 trial tests whether an inhaled solution of human interferon α1b can safely help children under 2 years old recover from respiratory syncytial virus (RSV) lower respiratory tract infections. The study compares the interferon treatment to a placebo, measuring improvements in breathing difficulty and other symptoms. Around 322 children will participate to see if this approach speeds up recovery and reduces illness severity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
human interferon α1b inhaled solution
What this could lead to
If effective, this inhaled treatment could provide a safe, targeted way to help young children recover faster from serious RSV lung infections.
What could go wrong
This is an early-phase trial with a moderate number of participants. The treatment may not prove more effective than placebo, and side effects from interferon are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Children's Hospital, Capital Institute of Pediatrics
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-••••